U.S. Markets closed

Beam Therapeutics Inc. (BEAM)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
47.91-0.54 (-1.11%)
At close: 04:00PM EST
48.00 +0.09 (+0.19%)
After hours: 05:39PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close48.45
Bid46.76 x 1000
Ask48.00 x 1000
Day's Range46.82 - 48.38
52 Week Range27.77 - 80.00
Avg. Volume838,327
Market Cap3.376B
Beta (5Y Monthly)1.82
PE Ratio (TTM)N/A
EPS (TTM)-4.19
Earnings DateFeb 27, 2023 - Mar 03, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est89.45
  • Motley Fool

    3 Cathie Wood Stocks Wall Street Thinks Can Soar 60% to 129%

    Cathie Wood is roaring back. Her flagship ARK Innovation ETF (NYSEMKT: ARKK) plunged 67% last year. But so far in 2023, the exchange-traded fund is up nearly 40%.  This impressive performance could be just the warm-up.

  • TipRanks

    Cathie Wood pours millions into these 2 stocks — this is what makes them attractive buys

    January has now been and gone and turned out to be a nice gift for investors. Battered by 2022’s bear, the tech-heavy Nasdaq, in particular, put in an excellent showing, seeing out the month ~11% into the green, in what amounted to its best start to a year since 2001. That signals the appetite for risk is on again and that will be good news for Cathie Wood, the ARK Investment CEO, whose investing style heavily favors disruptors - equities that are naturally positioned at the risky end of the sca

  • InvestorPlace

    7 CRISPR Stocks With the Best Long-Term Potential

    CRISPR technology has the potential to revolutionize the way we approach medicine. This technology has already been used in a variety of applications, including gene editing, gene therapy, and disease diagnosis. As a result, companies developing CRISPR-based products and services have seen significant valuation growth since inception, with many CRISPR stocks having excellent long-term upside potential in this regard. Several companies at the forefront of CRISPR technology have seen their stocks